What's Going On With Biohaven Stock Wednesday?
What's Going On With Biohaven Stock Wednesday?
Biohaven Ltd. (NYSE:BHVN) stock is moving lower Wednesday. The company recently presented several updates in different fields such as immunology and oncology at its Annual Investor Research and Development Day.
Biohaven Ltd.（紐約證券交易所代碼：BHVN）股價週三走低。該公司最近在其年度投資者研發日上發佈了免疫學和腫瘤學等不同領域的幾項最新消息。
The Details: The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two different studies and presented other updates.
詳情：該公司宣佈爲患者服用了某些癌症的新可能治療方法，展示了來自兩項不同研究的陽性數據，並介紹了其他最新情況。
Biohaven started the first patient's treatment in a Phase 1/2 trial for BHV-1510 which includes subjects with select advanced or metastatic epithelial cell tumors.
Biohaven 在 BHV-1510 的 1/2 期試驗中開始了第一位患者的治療，該試驗包括患有特定晚期或轉移性上皮細胞腫瘤的受試者。
In addition, Biohaven has entered into a agreement with Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) where Biohaven will finance the planned clinical trial and Regeneron will provide Libtayo allowing the companies to explore the combination of BHV-150 and Libtayo.
此外，Biohaven已與Regeneron Pharmicals, Inc.（納斯達克股票代碼：REGN）簽訂協議，由Biohaven爲計劃中的臨床試驗提供資金，Regeneron將向Libtayo提供Libtayo，允許兩家公司探索 BHV-150 和Libtayo的組合。
"We are extremely proud to advance our first oncology clinical program with a potentially best in class ADC [Antibody Drug Conjugate]," said Nushmia Khokhar, M.D., chief medical officer of oncology at Biohaven.
Biohaven腫瘤學首席醫學官努什米亞·霍哈爾醫學博士說：“我們非常自豪能夠使用可能處於同類最佳的ADC（抗體藥物偶聯物）來推進我們的第一個腫瘤學臨床項目。”
"With the initiation of this monotherapy study, we are one step closer to providing differentiated and superior treatment options to people living with cancer. We are also excited to work with Regeneron and efficiently explore BHV-1510 in combination with its PD-1 inhibitor Libtayo across a range of tumors."
“隨着這項單一療法研究的啓動，我們離爲癌症患者提供差異化和卓越的治療選擇又近了一步。我們也很高興能與 Regeneron 合作，高效地探索 BHV-1510 與其 PD-1 抑制劑的組合 Libtayo 跨越一系列腫瘤。”
Biohaven released positive Phase 1 data regarding BHV-8000 including positive regulatory input, allowing the start of programs aiming to prevent amyloid-related imaging abnormalities associated with certain medications and Parkinson's disease.
Biohaven 發佈了有關 BHV-8000 的陽性 1 期數據，包括積極的監管意見，這使旨在預防與某些藥物和帕金森氏病相關的澱粉樣蛋白相關影像學異常的計劃得以啓動。
Biohaven started five new clinical trials with BHV-7000 which is aimed at targeting two types of epilepsy, bipolar disorder, and major depressive disorder.
Biohaven 開始了五項新的 BHV-7000 臨床試驗，旨在針對兩種類型的癲癇、雙相情感障礙和重度抑鬱症。
Also, the company reported positive interim data from its ongoing Phase 1 study of BHV-1300 focused on investigating a new drug. Biohaven anticipates to have Myostatin program data for Phase 3 spinal muscular atrophy in the second half of 2024.
此外，該公司報告了正在進行的 BHV-1300 第一期研究的積極中期數據，該研究的重點是研究一種新藥。Biohaven預計將在2024年下半年獲得3期脊髓性肌萎縮症的肌抑素計劃數據。
Related Link: Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics
相關鏈接：破解密碼：了解分析師對Sage Therapeutics的評論
BHVN Price Action: Biohaven shares are trading 18.9% lower at $30.75 at the time of publication, per data from Benzinga Pro.
BHVN價格走勢：根據Benzinga Pro的數據，截至發佈時，Biohaven股價下跌18.9％，至30.75美元。
Image: Akava Photo from Pixabay
圖片：來自 Pixabay 的 Akava 照片